Navigation Links
Patient Doing Well Weeks After Historic 4-level AxioMed Viscoelastic Disc Replacement
Date:2/16/2017

AxioMed announced today the success of the first viscoelastic 4-level cervical case. Dr. Kingsley Chin, professor and Harvard trained surgeon, completed the procedure on Monday, Jan. 30 at Andrews Memorial Hospital in Kingston, Jamaica. The procedure was performed on a 55-year-old practicing female physician suffering from degenerative disc disease with radiculomyelopathy, as a result of degenerative cervical discs at levels C3-7. The patient failed conservative treatments prior to undergoing surgery.

Dr. Chin believes that viscoelastic disc technology will broaden the indication of cervical and lumbar treatment to include patients with abnormal alignment and motion, and will also treat patients that would classically qualify for fusion. Dr. Chin also believes that the design can be customized to treat scoliosis without fusion.

The AxioMed viscoelastic disc is a next-generation disc replacement that restores natural disc alignment and motion. The AxioMed disc is the most advanced in comparison to other disc replacement devices because its simple design and polymer core restores all natural disc characteristics such as height, lordosis, stability, and motion in the human spine. To view a side by side of disc motion vs. natural spine motion, visit https://www.youtube.com/watch?v=tq-lK5-p3sQ.

Dr. Chin, a former Bohlman fellow, said, “I can only imagine the pride Dr. Bohlman would feel with this type of innovation; he was always a proponent of anterior solutions to cervical spine disease.” Dr. Chin continued, “The AxioMed cervical disc is extremely easy to implant and has a great anatomical fit for restoring natural motion in the cervical spine.”

Jake Lubinski, president of AxioMed, was present during the procedure and added, “The simplicity and reliability of the AxioMed disc technology makes it ideal for surgeons of any level of training or technical proficiency to use the disc. Dr. Chin used very little fluoroscopy to get ideal placement, because you can actually see around the inserter and implant as it’s being implanted.”

Dr. Chin was born in Jamaica and has been doing surgery there for the last ten years. He expressed good fortune to be able to offer this technology to Jamaicans. “There is no need for expensive equipment, so doing this procedure in developing countries isn’t difficult; you can expect superior results over fusion or first generation disc replacement.” Dr. Chin believes this makes the AxioMed disc the ideal candidate for expanding medical tourism in countries like Jamaica, which is geographically advantageous for patients looking for AxioMed access while waiting for USA FDA clearance.

About AxioMed
Founded in 2001, AxioMed began its journey of exhaustively proving the Freedom® Disc through clinical studies in the USA and Europe, research, development, and testing. In 2014, KICVentures recognized the disc’s enormous potential and acquired the company into their healthcare portfolio. AxioMed owns an exclusive viscoelastic material license on its proprietary Freedom Disc technology.

Read the full story at http://www.prweb.com/releases/2017/02/prweb14071809.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. BERG Initiates Phase I/II Monotherapy Trial of BPM 31510-IV in Patients with Glioblastoma Multiforme (GBM)
2. Envisia Therapeutics Releases Interim ENV515 (Travoprost XR) Phase 2 Data Demonstrating 11-Month Duration-of-Action After a Single Dose in Patients With Glaucoma
3. The Conference Forum Announces 4th Annual “Patients as Partners” US Event
4. MedAvante Names Leader for Patient-Focused eSolutions
5. Asterias Announces Additional Motor Function Improvement at 6-months and 9-months Following Treatment with AST-OPC1 in Patients with Complete Cervical Spinal Cord Injuries
6. Resverlogix Provides Groundbreaking Results in Patients with Severe Kidney Impairments
7. Boston Biomedical to Highlight Data for Cancer Stemness Inhibitor Napabucasin in Patients with Colorectal Cancer at 2017 ASCO GI
8. Harris Poll: Only Nine Percent of U.S. Consumers Believe Pharma and Biotechnology Put Patients over Profits; Only 16 Percent Believe Health Insurers Do
9. Malaria Drug Successfully Treats 26-year-old Brain Cancer Patient
10. Vtesse Announces Dosing of First Patient in Australia in Phase 2b/3 Clinical Trial of VTS-270 in Niemann-Pick Type C1 Disease
11. Invitae acquires patient-centered data company AltaVoice, creating new offerings to advance research and access to care for patients with inherited and rare diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Md. , March 23, 2017  Northwest ... developing DCVax® personalized immune therapies for solid tumor ... the $7.5 million financing it announced last Friday, ... sold to several institutional investors securities totaling 28,843,692 ... per share, and 10,000,000 shares of Class C ...
(Date:3/23/2017)... Branford, CT (PRWEB) , ... March 23, 2017 ... ... Counsel, LLC, was recently selected by the Connecticut Technology Council (CTC) as a ... honored at CTC’s thirteenth annual Women of Innovation Awards Dinner. , The dinner ...
(Date:3/23/2017)... , March 23, 2017  Agriculture technology company ... A financing and note conversion to commercialize its Cool ... is focused on developing products that are simultaneously profitable ... million in the last 18 months. This latest round ... Bridge Venture Partners. The company,s primary ...
(Date:3/22/2017)... ... 2017 , ... Researchers face a fundamental challenge as they ... tissues, bones, even whole organs to implant in people to treat disease or ... the developing tissue. , Current bioengineering techniques, including 3-D printing, can’t fabricate ...
Breaking Biology Technology:
(Date:2/26/2017)... , Feb. 25, 2017  Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... Recidivism and Reentry. "Too often, too ... prisons and county jails are trying to tackle ... inmates and friends and family members. While significant steps ...
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
(Date:2/13/2017)... 13, 2017 Former 9/11 Commission border counsel ... Janice Kephart of Identity Strategy Partners, LLP, ... Trump,s "Executive Order: Protecting the Nation From Foreign ... "As President Trump,s ,Travel Ban, Executive Order ... essentially banned the travel ban, it is important that ...
Breaking Biology News(10 mins):